Daklinza (daclatasvir) / BMS 
Welcome,         Profile    Billing    Logout  
 32 Diseases   5 Trials   5 Trials   1782 News 


«12345678910111213...1314»
  • ||||||||||  Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    Clinical, Journal:  Response And Tolerability Of Sofosbuvir Plus Daclatasvir In Elderly Patients With Chronic Hepatitis-C. (Pubmed Central) -  Apr 17, 2020   
    SOF in combination with either IFN or DAC is an equally efficacious and effective treatment regimen for patients on maintenance HD, especially in resource-poor countries. Direct acting antiviral drug therapy is highly efficacious and safe for the treatment of HCV in older adults.
  • ||||||||||  Daklinza (daclatasvir) / BMS
    Journal:  Effects of Age on Treatment of Chronic Hepatitis C with Direct Acting Antivirals. (Pubmed Central) -  Apr 14, 2020   
    Direct acting antiviral drug therapy is highly efficacious and safe for the treatment of HCV in older adults. The high efficacy and tolerance of interferon-free regimens is confirmed in elderly patients in real-life conditions.
  • ||||||||||  Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    Trial initiation date:  the Pulmonary Safety of Antihepatitis C Treatment (clinicaltrials.gov) -  Mar 30, 2020   
    P=N/A,  N=50, Not yet recruiting, 
    A severe form of CryoVas and peripheral neuropathy were associated with lack of response of HCV-CryoVas to DAA therapy. Initiation date: Dec 2019 --> Jun 2020
  • ||||||||||  Daklinza (daclatasvir) / BMS
    Clinical, Journal:  Direct-acting antiviral Therapy Is Safe and Effective in Pediatric Chronic Hepatitis C: The Public Health Perspective. (Pubmed Central) -  Mar 20, 2020   
    Daclatasvir+sofosbuvir+ribavirin for 24 weeks was well tolerated and efficacious in HCV genotype-3-infected patients with compensated cirrhosis, with SVR12 outcomes comparable to previously reported outcomes in patients treated with this regimen for 12-16 weeks. The study demonstrates that the decentralized algorithm-based public-health programme can ensure high efficacy (SVR-12, 98.2%) and low-cost DAA based treatment of pediatric patients with CHC.
  • ||||||||||  Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    Journal:  Polymorphism in IFNL3/IL28B gene and risk to non-cirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy. (Pubmed Central) -  Mar 20, 2020   
    Our data revealed that the TT (minor) genotype of IFNL3 (rs12979860) and GG (minor) genotype of IFNL3 (rs8099917) exhibited significant association with chronic HCV genotype 3 infection when compared with controls. The results of treatment response showed that CC (major) genotype of IFNL3 (rs12979860) and TT (major) genotype of IFNL3 (rs8099917) are associated with likelihood of achieving a higher sustained virological response (SVR), to combined daclatasvir and sofosbuvir therapy, in genotype 3 infected HCV patients, whereas the individuals with TT (minor) genotype of IFNL3 (rs12979860) and GG (minor) genotype of IFNL3 (rs8099917) are more susceptible to chronic HCV infection and treatment relapse, suggesting a role of IFNL3 (rs12979860) and (rs8099917) in the treatment outcome of combined daclatasvir and sofosbuvir therapy in chronic HCV genotype 3 infection.
  • ||||||||||  Daklinza (daclatasvir) / BMS
    Clinical, Journal:  Efficacy and safety of sofosbuvir-based therapy in hepatitis C virus recurrence post living donor liver transplant: A real life egyptian experience. (Pubmed Central) -  Mar 20, 2020   
    The results of treatment response showed that CC (major) genotype of IFNL3 (rs12979860) and TT (major) genotype of IFNL3 (rs8099917) are associated with likelihood of achieving a higher sustained virological response (SVR), to combined daclatasvir and sofosbuvir therapy, in genotype 3 infected HCV patients, whereas the individuals with TT (minor) genotype of IFNL3 (rs12979860) and GG (minor) genotype of IFNL3 (rs8099917) are more susceptible to chronic HCV infection and treatment relapse, suggesting a role of IFNL3 (rs12979860) and (rs8099917) in the treatment outcome of combined daclatasvir and sofosbuvir therapy in chronic HCV genotype 3 infection. Different SOF-based regimens were effective with high SVR12 rates in a difficult-to-treat population, recurrent HCV post LDLT.
  • ||||||||||  Daklinza (daclatasvir) / BMS
    Trial completion, Trial completion date, Trial primary completion date:  Early Post-marketing Study of Daclatasvir (Daklinza) in the Treatment of Chronic Hepatitis C (CHC) in Adults (clinicaltrials.gov) -  Mar 18, 2020   
    P=N/A,  N=10, Completed, 
    The miniaturized Sito-GBBVs constitute a promising strategy to overcome key biological barriers facing hepatocytes specific delivery of Daclatasvir. Recruiting --> Completed | Trial completion date: Apr 2019 --> Aug 2019 | Trial primary completion date: Apr 2019 --> Aug 2019
  • ||||||||||  Journal:  Developments in the treatment of HCV genotype 3 infection. (Pubmed Central) -  Mar 14, 2020   
    This also includes patients infected with GT3 subtypes such as GT3b where multiple DAA-resistant substitutions occur naturally. Unless new drugs with non-overlapping drug-resistant profiles are discovered, perhaps a pegIFN-based therapy may be beneficial in select patient populations with high-level multiple DAA-resistant substitutions.
  • ||||||||||  Daklinza (daclatasvir) / BMS
    [VIRTUAL] COST-UTILITY ANALYSIS OF NEW ANTIVIRAL TREATMENTS FOR NON-GENOTYPE 1 HEPATITIS C VIRUS IN CHINA- A SOCIETAL PERSPECTIVE () -  Mar 8, 2020 - Abstract #ISPOR2020ISPOR_1929;    
    As for genotype 3, the combination of sofosbuvir and daclatasvir was the most cost-effective...CONCLUSIONS : For non-genotype 1 hepatitis C patients in China, DAAs are more cost-effective than PR, and they produce better health outcomes and higher quality of life. More importantly, reasonable price reduction of DAAs will increase drug affordability and is of great significance for the global strategy to eliminate viral hepatitis.
  • ||||||||||  Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    [VIRTUAL] IMPACT OF HCV CLEARANCE ON NK CELLS AND HIV TRANSCRIPTION IN COINFECTED SUBJECTS ([VIRTUAL]) -  Mar 2, 2020 - Abstract #CROI2020CROI_922;    
    Downregulation of NK cell activation was observed immediately after HCV clearance although some markers rebounded one year later, in concomitance with increased transcriptional activity of HIV reservoir. This may be reflecting the priming of NK cells by the residual HIV transcription and might point out a role for NK cells in shaping HIV persistence.
  • ||||||||||  Daklinza (daclatasvir) / BMS
    [VIRTUAL] HIV COINFECTION AND RISK OF MORBIDITY AND MORTALITY IN HCV PATIENTS TREATED BY DAA ([VIRTUAL]) -  Mar 2, 2020 - Abstract #CROI2020CROI_913;    
    After adjustment, HIV co-infection was not associated with a higher risk of liver-related events (HR=0.67 95%CI: 0.27 ; 1.67) or liver-related-mortality (HR=0.94 95%CI: 0.19 ; 4.67), but the risk of non-liver-related mortality (HR=2.67 95%CI: 0.97 ; 7.37) tended to be higher in HIV/HCV co-infected. After DAA treatment, SVR rates were not impacted by HIV co-infection, the risk of liver-related events and liver-related mortality were similar between HIV/HCV co-infected and HCV mono-infected but HIV co-infection tended to increase the risk of non-liver-related mortality.
  • ||||||||||  [VIRTUAL] RESISTANCE ANALYSIS IN HCV-3–INFECTED PATIENTS WITHIN THE ITALIAN NETWORK VIRONET-C ([VIRTUAL]) -  Mar 2, 2020 - Abstract #CROI2020CROI_897;    
    Moreover, 14.8% of pts were treated with suboptimal regimens for GT3: 3DRBV (Paritaprevir/r+Ombitasvir+Dasabuvir, N=15), SOF+Simeprevir (N=1) or SOF/ Ledipasvir (LDV)+RBV (N=4)...The presence of natural NS5A RAS before treatment was associated with failure. Further analyses are needed to confirm this observation, particularly for the new current regimens.
  • ||||||||||  Daklinza (daclatasvir) / BMS
    Mutagenicity evaluation of 2,7-diaminofluorene and 2,7-diaminocarbazole derivatives for use in drug discovery (Exhibit Hall D, Pennsylvania Convention Center) -  Feb 13, 2020 - Abstract #ACSSp2020ACS_Sp_4127;    
    Daclatasvir, a well-known HCV NS5A protein inhibitor reported by Bristol-Myers Squibb (BMS) in 2010, shows high antiviral activities against HCV...Likewise in carbazole cases compounds having long alkyl groups at the N9 position were found to be non-mutagenic. We discovered that 2,7-diaminofluorene and 2,7-diaminocarbazole moieties can be employed in drug discovery without necessarily causing mutation problems through proper modification at the C9 or N9 position.
  • ||||||||||  pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie, Daklinza (daclatasvir) / BMS
    Clinical, Journal:  COMBINED NS5A & NS5B NUCLEOTIDE INHIBITOR THERAPY FOR PATIENTS WITH CHRONIC HEPATITIS C WITH STAGE 5 CHRONIC KIDNEY DISEASE ON HEMODIALYSIS. (Pubmed Central) -  Feb 13, 2020   
    We discovered that 2,7-diaminofluorene and 2,7-diaminocarbazole moieties can be employed in drug discovery without necessarily causing mutation problems through proper modification at the C9 or N9 position. Full dose sofosbuvir i.e. 400 mg, in combination with NS5A inhibitors daclatasvir or ledipasvir is found to be safe and effective in patients with end stage renal disease, who are on maintenance hemodialysis.
  • ||||||||||  voxilaprevir (GS-9857) / Gilead, Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    Clinical, Journal:  A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients. (Pubmed Central) -  Feb 9, 2020   
    P4
    Our study demonstrates safety, efficacy and functional benefit of DCV/SOF treatment in KTR with chronic HCV infection. We provide data on rescue strategies for treatment failures due to present RAVs and amelioration of hepatic function and glucose tolerance.
  • ||||||||||  Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    Clinical, Journal:  Effect of direct-acting antivirals on corrected QT interval and cardiac functions in patients with chronic hepatitis C virus infection. (Pubmed Central) -  Feb 8, 2020   
    The current national protocol of HCV infection treatment with direct-acting antiviral agents used in Egyptian patients has a good cardiac safety profile. Such treatments have no effect on QTc interval, left and right ventricular functions except for a decrease in RV GLS in those with no liver cirrhosis and a reduction in lateral mitral E' velocity in those with liver cirrhosis both remained within the normal reference range.
  • ||||||||||  Daklinza (daclatasvir) / BMS
    Journal:  Progress of antiviral therapy for hepatitis C virus-related decompensated cirrhosis (Pubmed Central) -  Feb 1, 2020   
    Furthermore, approximately 15.5% ~ 49% of patients waiting for liver transplantation after treatment with DAAs do not require liver transplantation for short-term and 10.3% ~19.2% of patients receiving SOF/LDV, and SOF combined with DCV not needed liver transplantation. Thus, the clinical application of DAAs provides a safe and reliable antiviral treatment plan for hepatitis C virus-related decompensated stage cirrhosis.
  • ||||||||||  Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    Journal:  A proof-of-concept study in HCV-infected Huh7.5 cells for shortening the duration of DAA-based triple treatment regimens. (Pubmed Central) -  Jan 15, 2020   
    Although a virologic breakthrough occurred after an intermittent treatment regimen at the low fixed dose, the high fixed dose cured HCV-positive Huh7.5 cells with intermittent treatment. In conclusion, HCV is persistently present below detectable levels in HCV-infected Huh7.5 cells for a long time after treatment, and a shortened therapy duration is associated with an increased risk of virologic relapse, but virologic relapse or breakthrough might be avoided by treatment with a combination of more highly effective DAAs.